Critique: Teen temptations beware: MAHA-era FDA gives vapes, tanning beds a boost

Source: axios
Authors: Avery Lotz
URL: https://www.axios.com/2026/05/15/fda-maha-vape-tanning-booths-teen-temptations

## What the article reports
The FDA authorized its first fruit-flavored vaping products for adults and signaled reduced enforcement priority against some unauthorized products, while also withdrawing a long-pending proposal to ban minors from tanning beds. The piece places both moves in the context of the MAHA era under RFK Jr. and notes that former FDA Commissioner Marty Makary reportedly left partly over the vaping decision. Three critics and one cautiously mixed voice comment; no administration or industry defenders are quoted.

## Factual accuracy — Adequate
Most specific claims check out or are appropriately hedged. The piece correctly notes the American Academy of Pediatrics opposed the flavored vape authorization, attributes the Makary departure to reporting (using "reportedly" twice), and cites HHS's on-record statement about the tanning-bed rule withdrawal. The "nearly threefold increase in melanoma risk" is attributed to "a recent study" — no citation, date, journal, or author, making it unverifiable from the text. Mitch Zeller's tenure (2013–2022) at FDA's Center for Tobacco Products is a specific, checkable detail. The characterization of the enforcement guidance as a "get-out-of-jail-free card" is attributed to Zeller, so it's properly sourced, but no rebuttal is offered. No clear factual errors are visible, but the unsourced "recent study" and the opaque framing of the Makary ouster reduce confidence.

## Framing — Tendentious

1. **Headline:** "Teen temptations beware: MAHA-era FDA gives vapes, tanning beds a boost" — the word "boost" implies industry favoritism as settled fact; "teen temptations" editorializes before the first sentence. Neither phrase is attributed.
2. **"The moves risk weakening federal efforts to protect teens"** — presented in authorial voice as established risk, not as one interpretation. No one within the administration or industry is given space to contest this framing.
3. **"tumultuous shift in priorities"** — "tumultuous" is an unattributed characterization; a neutral version would describe what changed and let the reader assess its nature.
4. **"emboldening industries that market addictive or high-risk products"** — again authorial voice; "emboldening" carries strong negative connotation without attribution.
5. **"We're absolutely going backwards"** is the closing expert quote in the vaping section, and "restart the public health clock" closes the piece — both critical framings hold the last word in each section, a sequencing choice that steers rather than informs.

## Source balance

| Voice | Affiliation | Stance |
|---|---|---|
| Mitch Zeller | Former FDA CTP director (2013–2022) | Critical |
| Bonnie Halpern-Felsher | Stanford pediatrics; founder of REACH Lab | Critical |
| Hunter Shain | UC San Francisco dermatology professor | Critical |
| HHS spokesperson (paraphrase) | Administration | Neutral/defensive |
| Rich Danker (mentioned, not quoted) | RFK Jr. spokesperson who resigned | Implicitly critical |

**Ratio: 3 substantive critical voices : 0 supportive/defending voices : 1 neutral paraphrase.**
No industry representative, no current FDA official, no independent researcher who sees merit in the flavored-vape authorization or the tanning-bed rule withdrawal is quoted. Even Zeller's one cautiously positive remark — that the authorized company "appear to have strong age verification" — is quickly followed by his criticism.

## Omissions

1. **Administration or FDA defense of the vaping authorization.** The FDA's own press release is referenced but not quoted or linked. The public-health rationale the agency offered (adult smokers switching from combustibles) is absent — context that would let readers evaluate the tradeoff rather than only the risk side.
2. **Historical context on enforcement discretion.** The piece implies the new enforcement-guidance posture is novel wrongdoing. Prior FDA enforcement discretion policies under previous administrations — including the Obama and Biden eras — are not mentioned, making the comparison impossible.
3. **Industry or independent scientific voices on flavored vapes.** A number of researchers have published on the harm-reduction potential of flavored e-cigarettes for adult smokers. None appear.
4. **Tanning-bed rule history.** The proposal being withdrawn was described only as "decade-old." Why it stalled across multiple administrations — both Democratic and Republican — is unexamined, which would materially affect how readers interpret the withdrawal.
5. **The "recent study" on melanoma risk** lacks any citation. Readers cannot assess its methodology, sample size, or peer-review status.

## What it does well

- **Attributes the Makary departure carefully:** "reportedly resisted" and "reportedly contributed" signal appropriate uncertainty about an unconfirmed claim.
- **On-record sourcing:** all three expert voices are named with specific institutional affiliations — "a Stanford University pediatrics professor," "a dermatology professor at UC San Francisco" — rather than anonymous.
- **Concise structural separation** of the vaping and tanning-bed issues allows readers to track two distinct policy threads in a short piece.
- **Includes the administration's own language:** quoting HHS directly — "Withdrawal of the proposed rule does not change the established science on UV exposure" — gives readers the official position on the tanning-bed decision, even if unelaborated.
- **Zeller's mixed remark** ("the company that won authorization appear to have strong age verification") is included rather than omitted, which is a small but real nod toward complexity.

## Rating

| Dimension | Score | One-line justification |
|---|---|---|
| Factual accuracy | 7 | No clear errors, but "a recent study" on melanoma is unverifiable and the Makary departure is hedged rather than confirmed |
| Source diversity | 4 | Three named critics, zero defenders; HHS is paraphrased once; a 3:0 critical ratio with no industry or pro-authorization voice |
| Editorial neutrality | 4 | Headline, lede, and section-closing quotes consistently frame decisions as harmful; interpretive claims ("tumultuous," "emboldening") appear in authorial voice without attribution |
| Comprehensiveness/context | 5 | Tanning-bed and vaping risks are covered; absent are the FDA's stated rationale, prior-administration enforcement precedents, and harm-reduction arguments for flavored vapes |
| Transparency | 7 | Byline present, affiliations stated for all experts; no disclosure of whether Axios sought industry comment; FDA press release referenced but not linked |

**Overall: 5/10 — A reported piece with real named sources that nonetheless presents contested policy decisions almost entirely through critics' voices, with loaded framing embedded in authorial prose.**